Akten

Lidocaine Hydrochloride

Method of action: Anesthetic, Antiarrhythmic, Antipruritics, Incl. Antihistamines, Anesthetics, Etc, Local Anesthetic, Lubricating

Treatment option: Anesthesia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Akten

Quick Facts

Property	Description
Active ingredient	Lidocaine Hydrochloride
Form	Ophthalmic Gel (Topical)
Pharmacological class	Amide-Type Local Anesthetic
Common use	Inducing Surface Anesthesia
Origin	Synthetic (Acetamide Derivative)

What Type of Medicine is Akten?

Akten is a sterile, single-ingredient prescription medication primarily classified as an amide-type local anesthetic and an ophthalmic anesthetic. Its active component is Lidocaine Hydrochloride, which is a synthetic compound derived from Acetamide. Akten is utilized in scenarios requiring temporary numbing of the eye's surface, such as preparing the patient for minor diagnostic tests or procedures.

Composition and Physical Form of Akten

the physical form of the preparation is a sterile, preservative-free ophthalmic gel, intended for topical ophthalmic administration. The product is a monotherapy, meaning its anesthetic properties rely solely on the Lidocaine Hydrochloride ingredient. The formulation's primary differentiating factor is its use of an aqueous-based gel vehicle, achieved with excipients like Hypromellose. This highly viscous consistency is engineered to maximize the duration of contact between the active ingredient and the corneal surface, which supports the achievement of reliable surface anesthesia.

General Purpose: Why is Akten Used?

The general purpose of Akten is to induce surface anesthesia (temporary numbing) by halting local nerve signals at the point of application. Its high-level mechanism involves stabilizing the neuronal membrane, an action typical of a sodium channel blocker. This creates a reversible blockade of nerve impulse conduction. This localized and precise effect ensures the drug can effectively reduce patient discomfort during necessary short-duration ophthalmic procedures.

What side effects are possible with Akten?

Possible Side Effects and Safety Information

The safety profile for Akten, which is Lidocaine Hydrochloride Ophthalmic Gel, is characterized by adverse events primarily confined to the ocular surface and local application site. Regulatory documents classify the most frequently reported adverse reactions as common, meaning they occur in one percent or more of patients in clinical trials.

These common reactions include localized effects such as ocular hyperemia (eye redness), punctate keratitis (small erosions on the cornea), and minor corneal epithelial changes or defects. Patients may also experience localized ocular discomfort or a foreign body sensation.

Adverse Reaction Type	Examples (Common)
Ocular Disorders	Ocular Hyperemia, Punctate Keratitis, Corneal Epithelial Changes
Local Symptoms	Ocular Discomfort, Foreign Body Sensation

A critical safety consideration noted in official documents for this class of medicine relates to duration of use. Prolonged use of topical ocular anesthetics is explicitly associated with the risk of severe keratitis, which can progress to permanent corneal opacification and subsequent vision loss. The medicine is intended for short-term use, and this risk is tied to inappropriate extended exposure.

Regarding high-level safety restrictions, Akten is formally contraindicated in individuals who have a known hypersensitivity to the active ingredient, Lidocaine Hydrochloride, or any other component in the formulation. Furthermore, the safety and effectiveness of this ophthalmic gel have not been established for use in pediatric patients, though no overall differences were observed in the safety profile of older adults.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

The official regulatory profile for Akten overdose establishes that the primary concern relates to local ocular toxicity resulting from overexposure or prolonged use. Documented manifestations include the potential development of permanent corneal opacification and corneal ulceration, which may consequently lead to visual loss. This represents the most severe outcome officially described in connection with the misuse of this topical ophthalmic formulation. While acute emergencies linked to high plasma concentrations are known risks for local anesthetics generally, regulatory labeling states that systemic toxicity is not expected from the intended topical application route.

When to Seek Urgent Medical Help

Regulatory documentation mandates specific actions when exposure exceeds normal use or when adverse signs are present. Individuals must seek medical advice immediately following accidental ingestion of the gel. Seeking medical attention is also required if irritation persists or if any signs of general toxicity become apparent after exposure. The official procedural instruction for managing overexposure or toxicity is to provide symptomatic and supportive treatment. The prescribing information confirms that no specific antidote is available for this product.

Therapeutic Uses of Akten

What Akten Treats: Main Uses and Benefits

Akten is used across therapeutic domains where short-term symptom management is appropriate, applied to help with relief from procedural ocular pain and acute discomfort. This local anesthetic is commonly used to help with ocular surface anesthesia during ophthalmologic procedures. The medication is relevant for easing symptoms related to physical discomfort and is applied in clinical settings that involve acute symptom patterns, such as preparation for cataract surgery, intravitreal injections, and refractive laser treatments. The application helps maintain a sense of stability when symptoms are more noticeable, assisting with easing the overall symptom burden.

The primary therapeutic benefit contributes to improved comfort during periods of heightened symptoms. This symptomatic assistance is relevant for easing symptoms of increased neurological or muscular activity triggered by instrumentation. The use of this medication is relevant in contexts involving heightened systemic burden, supporting the performance of precise ophthalmic interventions, and provides support that helps ease the overall symptom burden, relevant when functional stability becomes affected during necessary procedures.

“This short-acting topical agent supports comfort during the momentary physical contact required for eye examination and intervention.”

Quick Fact: Support for Procedural Discomfort	Category	Therapeutic Focus
Primary Domain	Ocular Surface Anesthesia
Symptom Relieved	Procedural Pain and Discomfort
Benefit Provided	Supports Patient Comfort and Helps with Stability
Clinical Use	Short-Duration Ophthalmic Procedures

Eligibility and Restrictions for Use

The eligibility for using Akten (lidocaine hydrochloride ophthalmic gel) is governed by official regulatory documentation and focuses on specific population boundaries and administration context.

Contraindications and Restrictions

The most critical restriction is the absolute contraindication for any patient with a known history of hypersensitivity or allergic reaction to amide-type local anesthetics (the class of medicine that lidocaine belongs to) or to any component of the gel formulation.

Population Group	Regulatory Status	Restriction Context
Pediatric Patients	Safety and effectiveness not established	Use is not recommended by the FDA in this age group.
Adult Patients	Approved for use	Includes geriatric patients, where no specific restrictions are noted.
Pregnancy Status	Conditional use (Category B)	Use should occur only if clearly needed, as adequate human studies are lacking.
Lactation Status	Caution advised	Exercise caution when administering to a nursing mother.

Akten is intended solely for administration under the direct supervision of a healthcare provider and is not for patient self-administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory prescribing information for Akten (Lidocaine Hydrochloride Ophthalmic Gel) reflects the product's topical nature and minimal expected systemic exposure, resulting in few documented interaction constraints.

Official Interaction Profile Summary

Interaction Type	Regulatory Statement
Contraindicated Combinations	None. No medicinal products are explicitly prohibited from co-administration.
Systemic Drug-Drug Interactions	None documented. The label contains no dedicated section detailing specific metabolic or pharmacodynamic interactions with co-administered systemic drugs.
Food, Alcohol, or Herbal Products	None. The official documents do not contain specific restrictions or documented interaction patterns with food, alcohol, or herbal supplements.
Timing Requirements	None. No mandatory timing or separation requirements are formally mandated for the administration of other medicinal products.

Population-Specific Pharmacological Caution

The lack of documented specific interactions means the official profile does not impose interaction-related dosage adjustments. However, the general pharmacology described in the label includes a caution that conditions affecting liver function may alter lidocaine kinetics, and renal dysfunction may increase metabolite accumulation. This is an official consideration for systemic lidocaine, noted in the prescribing information despite the low expected systemic exposure from the ophthalmic gel.

Mechanism of Action

Blockade of Voltage-Gated Sodium Channels

Akten's mechanism centers on the reversible blockade of voltage-gated sodium channels ( Na v channels), which are membrane proteins crucial for propagating electrical impulses in nerve cells. The active molecule, Lidocaine, physically inhibits the inner pore of these channels, preventing the necessary influx of Na^+ ions required for neuronal depolarization.

Interruption of Peripheral Sensory Impulse Conduction

This molecular action directly leads to the interruption of the peripheral nociceptive signaling pathway at the site of application. By stabilizing the nerve cell membrane and halting the electrical impulse, the drug imposes a temporary, functional break in signal transmission along the sensory nerve fibers. This localized blockade of nerve excitability is the direct cause of the resulting abolition of afferent sensory signal transmission.

Impact of Local Tissue Chemistry

The effectiveness of this blockade is inherently linked to the surrounding local tissue chemistry. Since Lidocaine must cross the neuronal membrane as an uncharged molecule, its ability to reach its target is reduced in acidic environments, such as inflamed tissue. This pH-dependent constraint governs the boundaries of the mechanism's physiological action.

Dosage and Administration Information

How Akten is Used in Clinical Practice

Akten (lidocaine hydrochloride ophthalmic gel, 3.5%) is administered according to a strict, short-term protocol. The medicine is exclusively for Topical Ophthalmic Use and must be applied only to the ocular surface; it is explicitly designated as not for injection.

The central usage principle dictates that administration must always occur under the direct supervision of a healthcare provider in a clinical setting, such as a hospital or specialized facility. The medication is not intended for patient self-administration under any circumstances.

Standard Administration Regimen

The standard protocol requires the application of 2 drops of the ophthalmic gel onto the specific surface area of the eye where the procedure is planned. The frequency pattern is as-needed (procedural), allowing for reapplication only to maintain the necessary anesthetic effect for the short duration of the procedure. Use of the gel ceases immediately upon completion of the intervention, confirming its status as an acute, non-maintenance agent.

Population and Procedural Constraints

No specific dosage adjustment is required for the geriatric population, as clinical performance showed no significant difference compared to other adults. Safety and efficacy in pediatric patients are generally based on extrapolation from studies in older subjects and other lidocaine formulations, and the 2-drop regimen is used across the adult age spectrum. A critical procedural constraint is that the gel is supplied for single patient use, and the unused portion must be discarded immediately, ensuring adherence to the sterile, preservative-free administration guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Akten

Core Evidence for Ocular Surface Anesthesia

The core data for understanding the clinical research for Akten is derived primarily from a multi-center, randomized, controlled, double-blind study. This type of research explores the drug's profile compared to an inactive substance and supports the regulatory review process. This specific trial was studied for adult subjects who were preparing for an eye procedure that requires temporary numbness.

Studies monitored Akten gel alongside an identical-looking sham (placebo) gel and lower concentrations of the active ingredient. The main focus of the research was to monitor whether the sensation blockade endpoint could be successfully achieved within a set time period (five minutes) after the gel was applied. The studies monitored measurements related to the achievement of the sensation blockade endpoint when comparing subjects who received the Akten gel to those who received the sham gel.

Study Outcomes: Measuring Onset and Duration

Studies monitored the time to onset and duration of the sensation blockade, which are outcomes related to physical discomfort during necessary interventions. Studies monitored the time until the standardized sensation blockade began (onset) and the duration of that measured blockade.

Studies reported a mean time to onset of approximately one minute for the measured effect. The research reported that the mean duration of the measured blockade was approximately 15 minutes, with the effect observed to end in most subjects within about 30 minutes. This evidence provides context for the observed symptom patterns during short-term procedures. Because the medication is intended for temporary use, the study results reflect the specific, immediate conditions under which the research was conducted.

Research in Special Populations

Research explored how the effects of the gel were observed across different adult age groups. The available data include patterns observed when older adult patients (the geriatric population) participated in the studies. The research describes that no major differences in the observed response patterns were identified when comparing older adults to other adult patients in the available studies.

Data for certain groups remain insufficient, as dedicated studies focusing on the observed response patterns in pediatric populations (children) have not been performed for this specific gel formulation. Consequently, research is ongoing, and findings describe group patterns applicable primarily to adults.

Frequently Asked Questions (FAQ)

Common questions about Akten (FAQ)

Q: How quickly does the numbing effect of Akten start after application?

Studies and official information indicate that the measured sensation blockade, or numbing effect, begins quickly. Research reports the mean time to onset was approximately one minute after application.

Q: How long does the numbing effect of Akten usually last?

Clinical research found that the mean duration of the measured blockade was approximately 15 minutes. The effect was observed to end in most subjects within about 30 minutes, which provides context for why the medicine is used only for short-duration procedures.

Q: Can Akten be used during pregnancy, and what do official sources say?

Official documents classify the product under Pregnancy Category B. They advise that the medicine should only be used if clearly needed, as adequate, controlled studies in pregnant women are not available.

Q: If I rub my eye after Akten is applied, can it cause harm?

Patient guidance for this type of product generally advises against rubbing or touching the eye while it is numb. Because the anesthetic effect masks normal feeling, the numbing effect may prevent you from sensing an injury or damage to the eye.

Q: What should be reported to the healthcare provider immediately after receiving Akten?

Official guidance advises patients to report any symptoms that could indicate an allergic reaction, such as swelling of the face, tongue, or throat, or the appearance of hives. The official guidance indicates that any changes in vision should be reported immediately to a healthcare provider.

Q: What is the main purpose of Akten, since it is not used at home?

The official indication specifies that Akten is used to induce temporary surface anesthesia (numbing) on the eye. It is exclusively administered by a healthcare professional in a clinical setting to reduce discomfort during necessary ophthalmologic procedures.

Q: Is Akten the same as the lidocaine eye drops I've heard about?

No, official product information confirms that Akten is formulated as a sterile, preservative-free ophthalmic gel containing 3.5% lidocaine. This gel form is distinct from liquid lidocaine eye drops.

Q: What is the difference between Akten and other topical eye anesthetics?

Akten is specifically categorized as an amide-type local anesthetic with the active ingredient Lidocaine Hydrochloride. This classification describes the specific pharmacological group of medicine used to achieve temporary numbness on the eye's surface.

Q: Can Akten be used for pain in the eye outside of a procedure?

The official indication specifies its use for ocular surface anesthesia during ophthalmologic procedures. The official labeling does not include indications for general, non-procedural eye pain relief.

Q: Does Akten cause headache, and is this a normal side effect?

Headache is among the adverse effects that have been reported with the use of this product. Reports of side effects that continue or become bothersome are intended to be discussed with a healthcare professional.

Q: Is Akten safe for patients with a known allergy to other 'caine' anesthetics?

Akten is formally contraindicated in patients with a known history of hypersensitivity or allergy. This restriction applies to the active ingredient, Lidocaine, which belongs specifically to the amide-type local anesthetics.

Q: Is Akten a controlled substance?

Official regulatory documents confirm that Akten is a prescription-only medicine. However, it is not classified as a controlled substance under the regulatory schedules maintained by government bodies.

Q: Are there any reports of Akten causing blurry vision?

Blurry vision or other temporary changes in vision have been reported as a possible side effect of the medicine. Official guidance indicates that such changes should be reported immediately to a healthcare provider.

Q: Will I be able to drive home after receiving Akten?

Official patient guidance generally advises against driving or participating in activities that require clear vision until the full numbing effect has worn off and vision has returned to its normal state.

How should Akten be stored and disposed of?

How to Store and Dispose of Akten (Lidocaine Hydrochloride Ophthalmic Gel)

Akten must be stored at controlled room temperature, maintaining a range between 15 C to 25 C (59 F to 77 F). The product must be kept closed and protected from light; regulatory documents specify storage in the original carton until use.

Child Safety and Stability Constraints

For household safety, Akten must be kept out of the sight and reach of children. The vial is intended for single-patient use only and must be discarded after use, as its stability is not maintained once the single-use constraint is breached.